View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 17, 2020

Lead Pharma enters oral molecules development deal with Roche

Lead Pharma has signed a collaboration and license agreement with Roche for the development of oral small molecules to treat a broad range of immune-mediated diseases.

Lead Pharma has signed a collaboration and licence agreement with Roche for the development of oral small molecules to treat a broad range of immune-mediated diseases.

Immune-mediated disorders include joint diseases such as rheumatoid arthritis; skin diseases, including psoriasis and atopic dermatitis; as well as inflammatory bowel diseases.

According to the deal, Lead Pharma will get a €10m upfront payment and be eligible for research funding and pre-clinical milestone payments.

Total potential payments, including research, development, regulatory and sales milestones, may amount to €260m, in addition to royalties on worldwide sales.

The companies will jointly work in research activities up to the selection of a pre-clinical candidate. Later on, Roche will handle further development and global commercialisation.

The R&D partnership builds on Lead Pharma’s expertise in the discovery, design and optimisation of small-molecule treatments.

Lead Pharma CEO Frans van den Berg said: “Our ambition is to develop life-changing treatments for patients. We are delighted to team up with Roche to pursue this goal.

“Partnering is a key element of our strategy, this collaboration is yet another validation of the value of Lead Pharma’s innovation power.”

This is the second project Lead Pharma has partnered with a major pharma company under its Discover, Design and Deliver platform.

Roche Pharma Partnering global head James Sabry said: “We are committed to advancing innovative science and transformative medicines for people affected by different immune-mediated diseases.

“We are looking forward to further building on our expertise in this field and collaborating with Lead Pharma, aiming to make a difference for those patients.”

In 2015, Lead Pharma partnered with Sanofi to develop treatments for autoimmune disease.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology